Amal Aljuhani, Clinical Fellow at University of Toronto, shared a post on LinkedIn:
“Made It To The Wall Of Fame!
The wall of resilience. The wall reserved for some of the brightest minds in cancer research. And honestly? I still can’t believe myself. It feels surreal.
I’m beyond honored to share that I’ve received the 2026 American Society of Clinical Oncology (ASCO) Young Investigator Award from the Conquer Cancer, the ASCO Foundation, and to be the first Saudi to get there.
That’s a milestone I don’t take lightly. To carry my country onto that wall, in a field this competitive, alongside researchers I’ve looked up to for years, it’s a privilege I’m still processing.
None of this happened alone. Every time I tell someone I’m training in Canada, they say right away, ‘You must know David Cescon‘. And every time, with a big smile and huge pride, I get to say: he is my mentor. Dr.David Cescon, a ctDNA pioneer, a force in TNBC research, and PI on multiple practice-changing trials, believed in this before there was even a project to believe in. I’m endlessly grateful.
To Princess Margaret Cancer Centre and University Health Network , for being the environment where ideas like this can grow. To King Faisal Specialist Hospital and Research Center, where my foundation was built and where my long-term vision lives. And to Altis Labs and Pfizer for backing this work.
This award supports
RADIANT: Radiomics And liquid biopsy integration for prognostic assessment In metastatic breast cancer trajectories.
Work aimed at giving patients an earlier, more complete picture of their disease so we can act sooner. There’s a deeper story behind this one that I’ll share soon.
For now, still pinching myself, and just getting started.”
Other articles featuring Amal Aljuhani on OncoDaily.
